ArticleThe journal of the American College of Clinical Wound Specialists2013
Use of Topical Small Molecule Technology to Improve Patient Outcomes in the Diabetic Wound Care Setting.
Article in The journal of the American College of Clinical Wound Specialists, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients were chosen at random by primary investigator based upon initial presentation with dry, cracked, and/or reddened skin, with underlying complications from compromised microvasculature. Intervention was conducted by using topical products designed to utilize small molecule technologies, with a molecular weight of fewer than 500 Da, to deliver, via topical diffusion, nutrients and antioxidants through the skin layers to address issues stemming from inadequate blood flow to the dermis. An "all-in-one" moisturizing cleansing lotion was applied to the affected areas and washed gently with a warm damp cloth. After cleansing, the skin was treated with a moisturizing skin cream or a chlorhexidine-containing skin shield on areas with redness or advanced breakdown. All products contain dimethicone as an active ingredient and are classified as OTC skin protectants per approved FDA monographs. Patients were evaluated by the primary investigator for noticeable resolution or improvements in dryness, scaling, skin cracks, and erythema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.